Drugs / Daratumumab Hyaluronidase-fihj
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03590652 | Oct 2018 → Jul 2025 | refractory plasma cell neoplasm | University of California, San Diego | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05139225 Background | Oct 2021 → Jul 2026 | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daratumumab Hyaluronidase-fihj | “Drug: Daratumumab Hyaluronidase-fihj” NCT05139225 ↗ |
| Route | Subcutaneous | “1800mg SQ weekly x 8 weeks, biweekly x 8 doses, then monthly” NCT03590652 ↗ |